{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T16:55:41Z","timestamp":1783875341180,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Lung cancer is the leading cause of cancer mortality globally, with brain metastasis (BM) in 40% of advanced non-small-cell lung cancer (NSCLC) cases. In 15% of these cases, the brain is the sole affected organ (oligometastasis), which correlates with a better prognosis compared to widespread disease. It remains unclear if brain-only metastasis without systemic spread is due to the immune system\u2019s ability to control systemic tumor progression. We studied the immune cell compositions in NSCLC patients with BM, identifying novel patterns associated with BM, and specifcally with either oligo- or polymetastatic spread. Multi-parametric immune phenotyping of peripheral blood primarily showed alterations in the CD4<jats:sup>+<\/jats:sup> T cell compartment, with increased CD4<jats:sup>+<\/jats:sup> T<jats:sub>H<\/jats:sub>17 cells, and higher IL-17 levels in NSCLC BM patients compared to healthy individuals. Furthermore, CD4<jats:sup>+<\/jats:sup> T cells in BM patients exhibited lower CD73 expression and reduced effector memory differentiation. There was also decreased intratumoral infiltration and a distinct CD4<jats:sup>+<\/jats:sup> T cell profile in oligo-synchronous BM, both in the tumor microenvironment and peripheral blood, compared to polymetastatic BM patients. Additionally, CD73 was significantly upregulated in CD4<jats:sup>+<\/jats:sup> and T regulatory cells of oligo-synchronous (BM simulantously with primary-tumor diagnosis) BM. These findings suggest that CD4<jats:sup>+<\/jats:sup> T cells play a crucial role in the biology of NSCLC BM and potentially contribute to differences in metastatic patterns, as oligo-synchronous BM shows a more significant alteration in the CD4<jats:sup>+<\/jats:sup> T cell immune profile, both locally at the tumor site and systemically.<\/jats:p>","DOI":"10.1186\/s40478-025-02011-1","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T03:22:50Z","timestamp":1746760970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Altered CD4 T cell response in oligometatastic non-small cell lung cancer brain metastasis"],"prefix":"10.1186","volume":"13","author":[{"given":"Mais","family":"Alsousli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile L.","family":"Maire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Piffko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Matschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Glau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle","family":"Reetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Schneegans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gresa","family":"Emurlai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Asey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"R\u00fcnger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Peine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanthe","family":"Kropidlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Gempt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Glatzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Lamszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Joosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Mohme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Wikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"3","key":"2011_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2011_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/nou099","volume":"17","author":"JL Villano","year":"2015","unstructured":"Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG (2015) Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol 17(1):122\u2013128","journal-title":"Neuro Oncol"},{"issue":"4","key":"2011_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/2159-8290.CD-21-0010","volume":"11","author":"J Massague","year":"2021","unstructured":"Massague J, Ganesh K (2021) Metastasis-Initiating cells and ecosystems. Cancer Discov 11(4):971\u2013994","journal-title":"Cancer Discov"},{"key":"2011_CR4","doi-asserted-by":"publisher","first-page":"951805","DOI":"10.3389\/fonc.2022.951805","volume":"12","author":"A Piffko","year":"2022","unstructured":"Piffko A, Asey B, Duhrsen L et al (2022) Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer. Front Oncol 12:951805","journal-title":"Front Oncol"},{"issue":"6","key":"2011_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8(6):378\u2013382","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2011_CR6","doi-asserted-by":"publisher","first-page":"e50141","DOI":"10.1371\/journal.pone.0050141","volume":"7","author":"YA Lussier","year":"2012","unstructured":"Lussier YA, Khodarev NN, Regan K et al (2012) Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific MicroRNAs. PLoS ONE 7(12):e50141","journal-title":"PLoS ONE"},{"issue":"18","key":"2011_CR7","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J et al (2019) Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic Non-Small-Cell lung cancer: Long-Term results of a Multi-Institutional, phase II, randomized study. J Clin Oncol 37(18):1558\u20131565","journal-title":"J Clin Oncol"},{"issue":"3","key":"2011_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ijrobp.2018.06.400","volume":"102","author":"WJ Petty","year":"2018","unstructured":"Petty WJ, Urbanic JJ, Ahmed T et al (2018) Long-Term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic Non-Small cell lung Cancer. Int J Radiat Oncol Biol Phys 102(3):527\u2013535","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10422","key":"2011_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N et al (2024) Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 403(10422):171\u2013182","journal-title":"Lancet"},{"issue":"5","key":"2011_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"1","key":"2011_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12885-018-5214-8","volume":"19","author":"R Kim","year":"2019","unstructured":"Kim R, Keam B, Kim S et al (2019) Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. BMC Cancer 19(1):19","journal-title":"BMC Cancer"},{"issue":"7948","key":"2011_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","volume":"614","author":"E Karimi","year":"2023","unstructured":"Karimi E, Yu MW, Maritan SM et al (2023) Single-cell Spatial immune landscapes of primary and metastatic brain tumours. Nature 614(7948):555\u2013563","journal-title":"Nature"},{"key":"2011_CR13","doi-asserted-by":"crossref","unstructured":"Camy F, Karpathiou G, Dumollard JM et al (2020) Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status. J Immunother Cancer; 8(2)","DOI":"10.1136\/jitc-2020-000597"},{"issue":"1","key":"2011_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13058-019-1184-2","volume":"21","author":"C Riebensahm","year":"2019","unstructured":"Riebensahm C, Joosse SA, Mohme M et al (2019) Clonality of Circulating tumor cells in breast cancer brain metastasis patients. Breast Cancer Res 21(1):101","journal-title":"Breast Cancer Res"},{"issue":"38","key":"2011_CR15","doi-asserted-by":"publisher","first-page":"40836","DOI":"10.18632\/oncotarget.5696","volume":"6","author":"PN Harter","year":"2015","unstructured":"Harter PN, Bernatz S, Scholz A et al (2015) Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1\/PD-L1 immune checkpoints in human brain metastases. Oncotarget 6(38):40836\u201340849","journal-title":"Oncotarget"},{"issue":"10","key":"2011_CR16","first-page":"100230","volume":"2","author":"D Ikarashi","year":"2021","unstructured":"Ikarashi D, Okimoto T, Shukuya T et al (2021) Comparison of tumor microenvironments between primary tumors and brain metastases in patients with NSCLC. JTO Clin Res Rep 2(10):100230","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"2011_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41419-021-03410-7","volume":"12","author":"Z Song","year":"2021","unstructured":"Song Z, Yang L, Zhou Z et al (2021) Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. Cell Death Dis 12(1):106","journal-title":"Cell Death Dis"},{"issue":"10","key":"2011_CR18","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/eji.201646632","volume":"47","author":"A Cossarizza","year":"2017","unstructured":"Cossarizza A, Chang HD, Radbruch A et al (2017) Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol 47(10):1584\u20131797","journal-title":"Eur J Immunol"},{"issue":"14","key":"2011_CR19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.18632\/oncotarget.26659","volume":"10","author":"SA Greenberg","year":"2019","unstructured":"Greenberg SA, Kong SW, Thompson E, Gulla SV (2019) Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. Oncotarget 10(14):1399","journal-title":"Oncotarget"},{"issue":"4","key":"2011_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller N, Lozano E, Burkett PR et al (2014) Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit Proinflammatory Th1 and Th17 cell responses. Immunity 40(4):569\u2013581","journal-title":"Immunity"},{"issue":"9","key":"2011_CR21","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00262-019-02384-y","volume":"68","author":"YD Li","year":"2019","unstructured":"Li YD, Lamano JB, Lamano JB et al (2019) Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer. Cancer Immunol Immunother 68(9):1501\u20131513","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2011_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nri2742","volume":"10","author":"W Zou","year":"2010","unstructured":"Zou W, Restifo NP (2010) TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10(4):248\u2013256","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2011_CR23","doi-asserted-by":"publisher","first-page":"030006052092594","DOI":"10.1177\/0300060520925948","volume":"48","author":"G Chen","year":"2020","unstructured":"Chen G, Zhang P-G, Li J-S et al (2020) Th17 cell frequency and IL-17A production in peripheral blood of patients with non-small-cell lung cancer. J Int Med Res 48(6):0300060520925948","journal-title":"J Int Med Res"},{"issue":"7","key":"2011_CR24","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1111\/cas.14068","volume":"110","author":"L Song","year":"2019","unstructured":"Song L, Ma S, Chen L, Miao L, Tao M, Liu H (2019) Long-term prognostic significance of interleukin\u201017\u2010producing T cells in patients with non\u2010small cell lung cancer. Cancer Sci 110(7):2100\u20132109","journal-title":"Cancer Sci"},{"issue":"10","key":"2011_CR25","doi-asserted-by":"publisher","first-page":"e0139598","DOI":"10.1371\/journal.pone.0139598","volume":"10","author":"S Zhao","year":"2015","unstructured":"Zhao S, Wu D, Wu P, Wang Z, Huang J (2015) Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis. PLoS ONE 10(10):e0139598","journal-title":"PLoS ONE"},{"issue":"15","key":"2011_CR26","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1158\/1078-0432.CCR-12-3439","volume":"19","author":"W-W Sung","year":"2013","unstructured":"Sung W-W, Wang Y-C, Lin P-L et al (2013) IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res 19(15):4092\u20134103","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2011_CR27","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1111\/cas.13758","volume":"109","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Mishima K, Ohmura H et al (2018) Activation of central\/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. Cancer Sci 109(10):3032\u20133042","journal-title":"Cancer Sci"},{"key":"2011_CR28","doi-asserted-by":"crossref","unstructured":"Saxena A, Dagur PK, Biancotto A (2019) Multiparametric Flow Cytometry Analysis of Naive, Memory, and Effector T Cells. Methods Mol Biol.; 2032:129\u2013140","DOI":"10.1007\/978-1-4939-9650-6_8"},{"issue":"11","key":"2011_CR29","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1002\/eji.201242623","volume":"42","author":"GA Doherty","year":"2012","unstructured":"Doherty GA, Bai A, Hanidziar D et al (2012) CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur J Immunol 42(11):3062\u20133072","journal-title":"Eur J Immunol"},{"issue":"13","key":"2011_CR30","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/0008-5472.CAN-17-2405","volume":"78","author":"N Gourdin","year":"2018","unstructured":"Gourdin N, Bossennec M, Rodriguez C et al (2018) Autocrine adenosine regulates tumor polyfunctional CD73\u2009+\u2009CD4\u2009+\u2009effector T cells devoid of immune checkpoints. Cancer Res 78(13):3604\u20133618","journal-title":"Cancer Res"},{"issue":"4","key":"2011_CR31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2006-12-064527","volume":"110","author":"G Borsellino","year":"2007","unstructured":"Borsellino G, Kleinewietfeld M, Di Mitri D et al (2007) Expression of ectonucleotidase CD39 by Foxp3\u2009+\u2009Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110(4):1225\u20131232","journal-title":"Blood"},{"issue":"2","key":"2011_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11302-005-5302-5","volume":"2","author":"SP Colgan","year":"2006","unstructured":"Colgan SP, Eltzschig HK, Eckle T, Thompson LF (2006) Physiological roles for ecto-5\u2019-nucleotidase (CD73). Purinergic Signal 2(2):351\u2013360","journal-title":"Purinergic Signal"},{"key":"2011_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-065X.1998.tb01574.x","volume":"161","author":"R Resta","year":"1998","unstructured":"Resta R, Yamashita Y, Thompson LF (1998) Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 161:95\u2013109","journal-title":"Immunol Rev"},{"issue":"10","key":"2011_CR34","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1002\/(SICI)1521-4141(199810)28:10<2981::AID-IMMU2981>3.0.CO;2-D","volume":"28","author":"Y Yamashita","year":"1998","unstructured":"Yamashita Y, Hooker SW, Jiang H et al (1998) CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur J Immunol 28(10):2981\u20132990","journal-title":"Eur J Immunol"},{"key":"2011_CR35","doi-asserted-by":"crossref","unstructured":"Tu E, McGlinchey K, Wang J et al (2022) Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI Insight; 7(3)","DOI":"10.1172\/jci.insight.142843"},{"issue":"5","key":"2011_CR36","doi-asserted-by":"publisher","first-page":"8738","DOI":"10.18632\/oncotarget.14434","volume":"8","author":"Y Inoue","year":"2017","unstructured":"Inoue Y, Yoshimura K, Kurabe N et al (2017) Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget 8(5):8738\u20138751","journal-title":"Oncotarget"},{"issue":"21","key":"2011_CR37","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1158\/1078-0432.CCR-21-0206","volume":"27","author":"AM Miggelbrink","year":"2021","unstructured":"Miggelbrink AM, Jackson JD, Lorrey SJ et al (2021) CD4 T-cell exhaustion: does it exist and what are its roles in cancer? Clin cancer Research: Official J Am Association Cancer Res 27(21):5742","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"2","key":"2011_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2009.06.018","volume":"16","author":"DG DeNardo","year":"2009","unstructured":"DeNardo DG, Barreto JB, Andreu P et al (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2):91\u2013102","journal-title":"Cancer Cell"},{"key":"2011_CR39","doi-asserted-by":"crossref","unstructured":"Speiser DE, Chijioke O, Schaeuble K, M\u00fcnz C (2023) CD4\u2009+\u2009T cells in cancer. Nat Cancer:1\u201313","DOI":"10.1038\/s43018-023-00521-2"},{"key":"2011_CR40","doi-asserted-by":"crossref","unstructured":"Kruse B, Buzzai AC, Shridhar N et al (2023) CD4\u2009+\u2009T cell-induced inflammatory cell death controls immune-evasive tumours. Nature:1\u20138","DOI":"10.1038\/s41586-023-06199-x"},{"issue":"48","key":"2011_CR41","doi-asserted-by":"publisher","first-page":"83650","DOI":"10.18632\/oncotarget.19330","volume":"8","author":"P Yang","year":"2017","unstructured":"Yang P, Ma J, Yang X, Li W (2017) Peripheral CD4\u2009+\u2009naive\/memory ratio is an independent predictor of survival in non-small cell lung cancer. Oncotarget 8(48):83650\u201383659","journal-title":"Oncotarget"},{"issue":"4","key":"2011_CR42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2021.12.043","volume":"185","author":"H Gonzalez","year":"2022","unstructured":"Gonzalez H, Mei W, Robles I et al (2022) Cellular architecture of human brain metastases. Cell 185(4):729\u2013745 e720","journal-title":"Cell"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02011-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02011-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02011-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T03:22:55Z","timestamp":1746760975000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02011-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2011"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02011-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local ethics council of the Hamburg chamber for physicians under numbers Nr. PV5392 & Nr. PV4904 and was performed in accordance with the Helsinki Declaration of 1975.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}